108 results on '"Verbeek, Marcel M."'
Search Results
2. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy
3. Shotgun proteomics for the discovery of protein biomarkers for cerebral amyloid angiopathy
4. Full complement activation is associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease.
5. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy
6. Identification of CSF biomarkers for cerebral amyloid angiopathy using a targeted proteomics approach
7. Tissue inhibitor of matrix metalloproteinases 4: a novel marker associated with CAA
8. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective
9. Reply to: Letter for: Decreased cerebrospinal fluid A β 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy
10. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy
11. Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficit
12. Concordance of cerebrospinal fluid real‐time quaking‐induced conversion across the European Creutzfeldt–Jakob Disease Surveillance Network
13. Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy
14. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
15. Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
16. Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls
17. A disbalance of matrix metalloproteinases and their inhibitors in the cerebrospinal fluid from patients with cerebral amyloid angiopathy
18. Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy
19. Decreased purine metabolite levels in cerebrospinal fluid of transgenic cerebral amyloid angiopathy rats
20. Prevalence of sporadic cerebral amyloid angiopathy: A systematic review and meta‐analysis
21. Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis
22. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming
23. Monoamine oxidase A activity in fibroblasts as a functional confirmation ofMAOAvariants
24. Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy
25. Platelet‐derived growth factor receptor‐beta as a potential CSF biomarker for Alzheimer’s disease
26. Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease
27. International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease
28. Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy
29. Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity
30. Clinical presentation and long‐term follow‐up of dopamine beta hydroxylase deficiency
31. Confirmation of neurometabolic diagnoses using age‐dependent cerebrospinal fluid metabolomic profiles
32. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
33. α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism
34. O3‐09‐04: PLASMA AMYLOID β LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY
35. P3‐232: THE ASSOCIATION BETWEEN BLOOD‐BRAIN‐BARRIER DYSFUNCTION AND CSF P‐TAU IS MEDIATED BY BETA‐AMYLOID IN THE PRESENCE OF ELEVATED IL‐6
36. P3‐246: C‐REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY
37. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
38. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
39. [O3–10–03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY
40. ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE
41. ASSOCIATION BETWEEN NOCTURNAL AMYLOID BETA FLUCTUATIONS AND SLEEP
42. Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier
43. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
44. Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases
45. Dickkopf-related protein 3 is a potential Aβ-associated protein in Alzheimer's Disease
46. Saffold cardiovirus and multiple sclerosis: no evidence for an association
47. P2-117: MICRO-RNAS AS NOVEL BIOMARKERS IN AD: DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID
48. P2-051: THE HCMEC/D3 CELL LINE IS NOT SUITABLE AS A MODEL FOR Aβ TRANSPORT BY THE HUMAN BLOOD-BRAIN BARRIER
49. P4‐270: CORRELATIONS OF CSF BIOMARKER LEVELS WITH LATERAL VENTRICULAR CSF VOLUMES
50. P1-124: BINDING OF THE AB43 PEPTIDE TO APOLIPOPROTEIN E AND ITS ROLE IN CLEARANCE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.